Overview

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-30

Target enrollment:

Participant gender:

Summary

A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic non - squamous NSCLC with EGFR mutations and high PD-L1 expression.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Chest Hospital

Collaborator:

Innovent Biologics (Suzhou) Co. Ltd.